ISRCTN Registry, ResearchGate 2 Glucose control & metabolic markers in type 2 diabetes / pre-diabetes 14 g/day for 852 weeks 2024 dose-response meta-analysis of 36 RCTs (n=3 214) found clinically meaningful reductions in fasting glucose (9 mg/dL), HbA1c (0.32 %) and HOMA-IR (0.43)
Pharmacodynamic Considerations: Overlapping Biology, Not Opposing Effects Where the interaction picture becomes more nuanced is at the pharmacodynamic level
I guess this comes down to the growing use of social media and exposure to biohacking/optimal health gurus (i.e ben greenfield, thomas de lauer, huberman, ergogenic health etc)
Often undiagnosed but treatable: case vignettes and clinical considerations for assessing anxiety disorders in youth with autism spectrum disorder and intellectual disability
Gadde KM, Allison DB, Ryan DH, et al
Gastric Emptying Modulation Dual Pathway Effect Both components contribute to delayed gastric emptying through complementary mechanisms[5]: GLP3 delays gastric emptying primarily through GLP-1R and glucagon receptor pathways Cagrilintide slows gastric transit through amylin and calcitonin receptor activation Combined effects produce more sustained gastric delay than single agents Prolonged nutrient exposure in the small intestine enhances incretin release This dual-pathway gastric slowing mechanism may explain enhanced satiety and reduced caloric intake observed in combination studies
